Abravanel et al, 201225 | France | Retrospective | Allo-HSCT and auto-HSCT candidates | 88 | 51 | 65.9 | 6 months after transplant | Positive IgG/IgM/RNA | 2009–2010 | 36.4 | 0 | Adaltis/Wantai |
Ankcorn et al, 201847 | UK | Prospective | Allo-HSCT candidates | 144 | N/A | N/A | 4–18 | HEV-RNA/Ag | 2016 | N/A | 2.08 | N/A |
Furfaro et al 202024 | Italy | Retrospective | Allo-HSCT and auto-HSCT candidates | 563 | 48 | 56.5 | N/A | Positive IgG/RNA | 2010–2015, 2017–2019 | 6.04 | 3.4 | Wantai/Ultra |
Koenecke et al, 201226 | Germany | Retrospective | Allo-HSCT with elevated ALT | 52 | 41 | 62 | N/A | Positive IgG/RNA | 1998–2004 | 5.8 | 0 | Abbott |
Reekie et al, 201848 | UK | Cross-sectional | Allo-HSCT and auto-HSCT | 259 | N/A | N/A | N/A | HEV-RNA | 2013–2015 | N/A | 0.39 | N/A |
Swartling et al, 202049 | Sweden | Retrospective | Allo-HSCT candidates | 236 | N/A | N/A | 25 | Positive IgG/IgM/RNA | 2008–2015 | 4.7 | 3.4 | Diapro |
Tang et al, 201950 | China | Retrospective | Haploidentical allo-HSCT with elevated ALT | 177 | 26 | 63.3 | 36.9 | Positive IgG/IgM/RNA | 2014–2017 | N/A | 3.9 | MP Diagnostics |
Versluis et al, 201320 | The Netherlands | Retrospective | Allo-HSCT candidates | 328 | 50.4 | 54 | 40.9 | Positive IgG/IgM/RNA | 2006–2011 | 12.9 | 2.4 | Wantai |
Willemse et al, 201751 | The Netherlands | Retrospective | Allo-HSCT with elevated ALT | 130 | N/A | 53.8 | N/A | HEV-RNA | 2005–2015 | N/A | 4 | N/A |